293 related articles for article (PubMed ID: 23358330)
21. Inhibition of small GTPase RalA regulates growth and arsenic-induced apoptosis in chronic myeloid leukemia (CML) cells.
Zhu X; Li Y; Luo X; Fei J
Cell Signal; 2012 Jun; 24(6):1134-40. PubMed ID: 22330069
[TBL] [Abstract][Full Text] [Related]
22. Realgar transforming solution-induced differentiation of NB4 cell by the degradation of PML/RARα partially through the ubiquitin-proteasome pathway.
Hai Y; Wang X; Song P; Li JY; Zhao LH; Xie F; Tan XM; Xie QJ; Yu L; Li Y; Wu ZR; Li HY
Arch Pharm Res; 2019 Aug; 42(8):684-694. PubMed ID: 31214877
[TBL] [Abstract][Full Text] [Related]
23. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
[TBL] [Abstract][Full Text] [Related]
24. Effects of arsenic trioxide (As2O3) on leukemic cells from patients with non-M3 acute myelogenous leukemia: studies of cytotoxicity, apoptosis and the pattern of resistance.
Lehmann S; Bengtzen S; Paul A; Christensson B; Paul C
Eur J Haematol; 2001 Jun; 66(6):357-64. PubMed ID: 11488934
[TBL] [Abstract][Full Text] [Related]
25. Arsenic Trioxide overcomes cell adhesion-mediated drug resistance through down-regulating the expression of beta(1)-integrin in K562 chronic myelogenous leukemia cell line.
Guo-Bao W; Xiao-Qin C; Qi-Rong G; Jie L; Gui-Nan L; Yue L
Leuk Lymphoma; 2010 Jun; 51(6):1090-7. PubMed ID: 20470221
[TBL] [Abstract][Full Text] [Related]
26. Arsenic trioxide reduces drug resistance to adriamycin in leukemic K562/A02 cells via multiple mechanisms.
Zhao D; Jiang Y; Dong X; Liu Z; Qu B; Zhang Y; Ma N; Han Q
Biomed Pharmacother; 2011 Aug; 65(5):354-8. PubMed ID: 21775093
[TBL] [Abstract][Full Text] [Related]
27. [Apoptosis mechanism in human chronic myelogenous leukemia K562 cells induced by tetra-arsenic tetra-sulfide].
Ye QD; Gu LJ; Zhao YX; Zhao JC; Chen WG; Zhang B; Jiang LM
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Oct; 13(5):759-63. PubMed ID: 16277837
[TBL] [Abstract][Full Text] [Related]
28. With no interaction, knockdown of Apollon and MDR1 reverse the multidrug resistance of human chronic myelogenous leukemia K562/ADM cells.
Chen JR; Jia XH; Wang H; Yi YJ; Li YJ
Oncol Rep; 2017 May; 37(5):2735-2742. PubMed ID: 28358418
[TBL] [Abstract][Full Text] [Related]
29. VEGF depletion enhances bcr-abl-specific sensitivity of arsenic trioxide in chronic myelogenous leukemia.
Luo X; Feng M; Zhu X; Li Y; Fei J; Zhang Y
Hematology; 2013 Nov; 18(6):334-40. PubMed ID: 24129092
[TBL] [Abstract][Full Text] [Related]
30. Targeting P-Glycoprotein: Nelfinavir Reverses Adriamycin Resistance in K562/ADR Cells.
Liu W; Meng Q; Sun Y; Wang C; Huo X; Liu Z; Sun P; Sun H; Ma X; Liu K
Cell Physiol Biochem; 2018; 51(4):1616-1631. PubMed ID: 30497065
[TBL] [Abstract][Full Text] [Related]
31. Reversal effect of bufalin on multidrug resistance in K562/VCR vincristine-resistant leukemia cell line.
Zhai X; Lu J; Wang Y; Fang F; Li B; Gu W
J Tradit Chin Med; 2014 Dec; 34(6):678-83. PubMed ID: 25618972
[TBL] [Abstract][Full Text] [Related]
32. Arsenic sulfide nanoformulation induces erythroid differentiation in chronic myeloid leukemia cells through degradation of BCR-ABL.
Wang T; Wen T; Li H; Han B; Hao S; Wang C; Ma Q; Meng J; Liu J; Xu H
Int J Nanomedicine; 2019; 14():5581-5594. PubMed ID: 31413564
[TBL] [Abstract][Full Text] [Related]
33. Arsenic trioxide inhibits p-glycoprotein expression in multidrug-resistant human leukemia cells that overexpress the MDR1 gene.
Wei H; Su H; Bai D; Zhao H; Ge J; Wang B; Yao X; Ma L
Chin Med J (Engl); 2003 Nov; 116(11):1644-8. PubMed ID: 14642128
[TBL] [Abstract][Full Text] [Related]
34. Anti-miR-21 oligonucleotide sensitizes leukemic K562 cells to arsenic trioxide by inducing apoptosis.
Li Y; Zhu X; Gu J; Dong D; Yao J; Lin C; Huang K; Fei J
Cancer Sci; 2010 Apr; 101(4):948-54. PubMed ID: 20148895
[TBL] [Abstract][Full Text] [Related]
35. Knockdown of HOXA10 reverses the multidrug resistance of human chronic mylogenous leukemia K562/ADM cells by downregulating P-gp and MRP-1.
Yi YJ; Jia XH; Wang JY; Li YJ; Wang H; Xie SY
Int J Mol Med; 2016 May; 37(5):1405-11. PubMed ID: 27035504
[TBL] [Abstract][Full Text] [Related]
36. Relationship of expression of aquaglyceroporin 9 with arsenic uptake and sensitivity in leukemia cells.
Leung J; Pang A; Yuen WH; Kwong YL; Tse EW
Blood; 2007 Jan; 109(2):740-6. PubMed ID: 16968895
[TBL] [Abstract][Full Text] [Related]
37. Anti-proliferative effect of the abl tyrosine kinase inhibitor STI571 on the P-glycoprotein positive K562/ADM cell line.
Kotaki M; Motoji T; Takanashi M; Wang YH; Mizoguchi H
Cancer Lett; 2003 Sep; 199(1):61-8. PubMed ID: 12963124
[TBL] [Abstract][Full Text] [Related]
38. Targeting catalase but not peroxiredoxins enhances arsenic trioxide-induced apoptosis in K562 cells.
Song LL; Tu YY; Xia L; Wang WW; Wei W; Ma CM; Wen DH; Lei H; Xu HZ; Wu YL
PLoS One; 2014; 9(8):e104985. PubMed ID: 25115845
[TBL] [Abstract][Full Text] [Related]
39. TRIB2 knockdown as a regulator of chemotherapy resistance and proliferation via the ERK/STAT3 signaling pathway in human chronic myelogenous leukemia K562/ADM cells.
Ma X; Zhou X; Qu H; Ma Y; Yue Z; Shang W; Wang P; Xie S; Li Y; Sun Y
Oncol Rep; 2018 Apr; 39(4):1910-1918. PubMed ID: 29436678
[TBL] [Abstract][Full Text] [Related]
40. Properties of realgar bioleaching using an extremely acidophilic bacterium and its antitumor mechanism as an anticancer agent.
Chen P; Xu R; Yan L; Wu Z; Wei Y; Zhao W; Wang X; Xie Q; Li H
Biol Res; 2017 May; 50(1):17. PubMed ID: 28532516
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
